HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The spectrum of complement alternative pathway-mediated diseases.

AbstractSUMMARY:
The complement system has once again come into prominence in the therapeutic development arena. The recent approval of an inhibitory monoclonal antibody, eculizumab, which is directed against complement component C5 for the disease paroxysmal nocturnal hemoglobinuria has provided the initial validation of this system as a therapeutic target. Preclinical studies using animal models and human-derived samples demonstrate that inhibition of complement ameliorates many inflammatory and autoimmune disease manifestations. Major efforts continue to define the most optimal means to block complement activation in a cost-effective manner. Because the system is initiated through three pathways and generates at least six immunoregulatory and pro-inflammatory mediators, there is substantial complexity to this problem. One pathway, designated the alternative pathway, has recently been shown to play a particularly important role in preclinical disease models. Further evidence of the importance of the alternative pathway has been provided by studies of human diseases, where mutations or dysfunctional polymorphisms that promote activation of this pathway are highly associated with the diseases atypical hemolytic uremic syndrome, dense deposit disease, and age-related macular degeneration. This article reviews evidence in support of the essential role of the alternative pathway in the generation of tissue injury and the rationale for development of therapies that modulate its activity.
AuthorsV Michael Holers
JournalImmunological reviews (Immunol Rev) Vol. 223 Pg. 300-16 (Jun 2008) ISSN: 1600-065X [Electronic] England
PMID18613844 (Publication Type: Journal Article, Review)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Complement System Proteins
  • eculizumab
Topics
  • Animals
  • Antibodies, Monoclonal (immunology, therapeutic use)
  • Antibodies, Monoclonal, Humanized
  • Complement Pathway, Alternative (immunology)
  • Complement System Proteins (genetics, immunology)
  • Cytotoxicity, Immunologic
  • Female
  • Glomerulonephritis, Membranoproliferative (etiology, therapy)
  • Hemoglobinuria, Paroxysmal (etiology, therapy)
  • Hemolytic-Uremic Syndrome (etiology, therapy)
  • Humans
  • Immune Complex Diseases (etiology, therapy)
  • Mice
  • Polymorphism, Genetic
  • Pregnancy
  • Pregnancy Complications (etiology, therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: